Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC).

Andreas Dietz,Gunnar Wichmann,Michael Flentje,Rudolf Hagen,Oliver Koelbl,Frank Schreiber,Volker Schilling,Georg Maschmeyer,Ursula Schroeder,Christian Sittel,Thomas Lenarz,Jens Peter Klussmann,Orlando Guntinas-Lichius,Claudia Rudack,Thomas Foerg,Martin Westhofen,Hans-Juergen Welkoborsky,Dirk Esser,Swantje Held,Ulrich Keilholz

Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC).

2016

6025Background: To evaluate the impact of E added throughout IC and R on the rate of two-year functional laryngectomy free survival (fLFS). Methods: Untreated patients (pts) with stage III/IV LHSCC...

Keywords:

Cetuximab
Hypopharyngeal cancer
Physical therapy
Radiation therapy
Induction chemotherapy
Larynx
General surgery
Medicine
Laryngectomy
larynx preservation
Oncology
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations